2023
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna P, Farahdel E, Potenza M, Crowley M. The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. Expert Opinion On Pharmacotherapy 2023, 24: 835-847. PMID: 37074259, PMCID: PMC10197951, DOI: 10.1080/14656566.2023.2199921.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSelective norepinephrine reuptake inhibitorGeneralized anxiety disorderAnxiety disordersReuptake inhibitorsPediatric generalized anxiety disorderBetter long-term outcomesSecond-line treatmentNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsFirst-line interventionLong-term outcomesCombination of psychotherapyPrevalent psychiatric disordersEvidence-based statePediatric anxiety disordersArt pharmacotherapyModerate effect sizeFunctional outcomeEarly recognitionMood disordersElevated riskPsychiatric disordersBetter outcomesElectronic databases
2008
The Treatment of Pathologic Gambling
Brewer J, Grant J, Potenza M. The Treatment of Pathologic Gambling. Addictive Disorders & Their Treatment 2008, 7: 1-13. DOI: 10.1097/adt.0b013e31803155c2.Peer-Reviewed Original ResearchPharmacologic therapyPathologic gamblingSelective serotonin reuptake inhibitorsPharmacologic treatment studiesSerotonin reuptake inhibitorsStandardized outcome measuresComparison of interventionsPreliminary positive resultsSelf-help programReuptake inhibitorsOpioid antagonistSpecific therapyOutcome measuresConsistent efficacyTreatment studiesBehavioral treatmentLarger studyTherapySpecific subpopulationsResults MultiplePharmacotherapyTreatmentPositive resultsAvailable literatureEfficacy